Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Rtw Biotech (RTW) Share News

IN BRIEF: RTW Biotech lifts NAV on Biogen's USD85 million Alcyone deal

23rd Sep 2025 11:01

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Notes Biogen Inc's agreement announced last Thursday to acquire portfolio company Alcyone Therapeutics Inc for USD85 million upfront plus milestone payments. Says the deal represents a 242% uplift on RTW's USD2.1 million carrying value of Alcyone, adding USD5.0 million, or around 0.7%, to its August 31 NAV, where Alcyone represented approximately a 0.3% position. Alcyone is developing ThecaFlex DRx, an implantable device for intrathecal delivery of neurological therapies, which Biogen plans to deploy with its marketed drug Spinraza, with a launch targeted in 2028. The transaction its RTW's second portfolio takeout this year, following Merck & Co Inc's purchase of Verona Pharma PLC, and says it highlights embedded value in its private holdings. Read More

RTW Biotech Opportunities NAV falls in "volatile" period for biotech

11th Sep 2025 10:29

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said the biotech industry is navigating a "complex but increasingly constructive environment" as it reported a decline in its interim net asset value per share. Read More

IN BRIEF: RTW Biotech Opportunities joins FTSE all-share index

5th Sep 2025 09:27

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Says it will join the FTSE all-share index on September 22. This follows FTSE Russell's decision to include securities trading in non-sterling currencies. Chair William Simpson says the move "is likely to enhance our exposure to investors, develop greater UK and international investor awareness of RTW Bio, and provide increased long-term access to capital." Read More

UK earnings, trading statements calendar - next 7 days

4th Sep 2025 14:26

Read More

RTW Biotech joins Aquestive funding to support oral epinephrine

19th Aug 2025 10:05

(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday noted Aquestive Therapeutics Inc's announcement of a strategic funding agreement with funds managed by RTW Investments LP. Read More

Merck & Co snaps up respiratory drug maker Verona for USD10 billion

10th Jul 2025 09:06

(Alliance News) - Merck & Co Inc on Wednesday said it has struck a deal to acquire Verona Pharma PLC, bolstering its respiratory diseases offering. Read More

LONDON BRIEFING: Severn Trent "on track"; WPP makes non-exec next CEO

10th Jul 2025 07:53

(Alliance News) - Water utility Severn Trent and housebuilder Vistry backed guidance, while advertising firm WPP named a new chief executive. Read More

RTW Biotech hails Corxel obesity drug progress in US, China trials

24th Jun 2025 11:15

(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday highlighted clinical developments from Corxel Pharmaceuticals (Shanghai) Co Ltd, its second-largest portfolio holding, including the start of a US phase 2 trial and positive results from a China study of Corxel's lead obesity treatment, CX11. Read More

UK shareholder meetings calendar - next 7 days

2nd Jun 2025 12:36

Read More

RTW Biotech notes mixed updates across portfolio companies

30th May 2025 12:35

(Alliance News) - RTW Biotech Opportunities Ltd on Friday provided updates on three of its key listed holdings, highlighting both promising clinical trial results and a significant setback involving one of its biotech investments. Read More

RTW Biotech investee sees encouraging results in cardiac disease trial

19th May 2025 14:20

(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted investee Rocket Pharmaceuticals has reported "encouraging" data from a phase 1 clinical trial of its treatment for arrhythmogenic cardiomyopathy. Read More

RTW Biotech Opportunities notes positive trial data from investee

2nd May 2025 13:00

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted positive trial data from investee Artios Pharma, for the ongoing study of its lead candidate ART0380. Read More

RTW Biotech Opportunities closes new investment with Airna

3rd Apr 2025 17:23

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced a new investment into biotech company Airna, closing its oversubscribed USD155 million series B financing round. Read More

RTW Biotech underperforms benchmark but optimistic for 2025

31st Mar 2025 13:32

(Alliance News) - RTW Biotech Opportunities Ltd on Monday said it underperformed its benchmarks during 2024, while total net asset value climbed following the takeover of Arix Bioscience PLC. Read More

UK earnings, trading statements calendar - next 7 days

24th Mar 2025 16:14

Read More

RTW Biotech notes positive data in Kailera Therapeutics obesity trial

27th Jan 2025 10:15

(Alliance News) - RTW Biotech Opportunities Ltd on Monday said portfolio company Kailera Therapeutics has received positive results from a recent weight loss treatment trial. Read More

RTW Biotech participates in investment rounds worth USD300 million

17th Jan 2025 11:26

(Alliance News) - RTW Biotech Opportunities Ltd on Friday said it has made two separate investments as part of series A and C funding rounds in two clinical-stage firms. Read More

IN BRIEF: RTW Biotech makes further investment in Numab Therapeutics

14th Jan 2025 12:14

RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Makes additional investment in Series C extension of Numab Therapeutics, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Numab's CHF50 million, or USD54.5 million, extension, brought its total Series C funding to CHF180 million. Funds will be used to support its clinical development efforts. RTW Biotech first invested in Numab in May 2021. Read More

RTW Biotech invests in EUR65 million Alesta Therapeutics round

10th Jan 2025 14:18

(Alliance News) - RTW Biotech Opportunities Ltd said on Friday said it is participating in a EUR65 million Series A financing round for Alesta Therapeutics BV, a Leiden, Netherlands-based biotechnology company focused on developing novel oral therapies for rare diseases with unmet medical needs. Read More

RTW Biotech highlights "major milestone" as Corxel lands Sanofi deal

30th Dec 2024 08:52

(Alliance News) - RTW Biotech Opportunities Ltd on Monday reported two key developments at its Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd. Read More

FTSE 100 Latest
Value9,425.46
Change-20.97